Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Zilucoplan, now Zilbrysq, approved by FDA for AChR-positive gMG

The U.S. Food and Drug Administration (FDA) has approved zilucoplan, a once-daily injection therapy to now be marketed under the brand name Zilbrysq, for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). With this approval, Zilbrysq has now become the…

Povetacicept shows promise in MG mouse model

Treatment with the experimental therapy povetacicept (ALPN-303) reduced disease activity in a mouse model of myasthenia gravis (MG), according to data shared by its developer, Alpine Immune Sciences. Povetacicept also was tolerated well by healthy volunteers participating in a Phase 1 clinical trial. “Together, these data provide strong…